Whooping Cough
Aka: Whooping Cough, Bordetella pertussis, Pertussis
II. Epidemiology
- Incidence
- U.S. (2012)
- General Population: 41,000 cases/year (8.5 cases per 100,000)
- Infants: 88.7 per 100,000
- Mortality: 18 deaths (mostly infants)
- Worldwide: 30-50 million cases/year with 300,000 deaths/year
- U.S. (2012)
- Pertussis still affects children more than adults
- Infants younger than 6 months represent 38% of U.S. cases
- Children under age 5 years represent 71% of U.S. cases
- Pertussis is a common cause of adult Chronic Cough
- Pertussis is responsible for 20% of adults and teens with severe cough >2 weeks presenting to ED
- Most cases in children occur in over age 10 years
- With waning immunity, teens and adults are reservoir
- Immunity wanes by as much as 42% per year since last DTaP
- Klein (2012) N Engl J Med 367(11): 1012-9 [PubMed]
- Infants are infected by adults
- Infants account for most of Pertussis-related mortality (especially under age 3 months)
- Infant immunity <1 year is incomplete
- Infants comprise >50% of all childhood infections
- Infection most severe in infants including death
III. Etiologies
- Bordetella pertussis (most common)
- Bordetella parapertussis
- Bordatella Bronchiseptica
IV. Pathophysiology
- Extremely contagious with 80-100% secondary attack rate in those susceptible
- Droplet spread with inhalation into airways
- Pertussis releases toxins that damage the respiratory epithelium and result in mucosal injury
- Incubation period: 7 to 10 days (incubation may be as long as 3 weeks)
- Contrast with most viral infections which incubate for a few days
V. Findings: Signs and symptoms
- General Findings
- Variable severity based on age and immunity
- Pertussis without classic Paroxysmal coughing spasms is common
- Especially in teens and adults with prolonged cough (>30% of Pertussis cases)
- Exam is often normal (although fine rales may be present)
- Catarrhal Stage (1-2 weeks, may be as short as a few days in infants <3 month)
- Indistinguishable from a Common Cold (but highly contagious)
- Low grade fever
- Malaise
- Mild Conjunctivitis
- Mild cough
- Pharyngitis
- Rhinorrhea or Rhinitis
- Sneezing
- Lacrimation
- Paroxysmal cough Stage (2-4 weeks with peak at 2 weeks)
- Infants under age 6 months
- Apnea
- Cyanosis
- Bradycardia
- Persistent cough (not in spasms, and whooping is uncommon)
- Decreased oral intake
- Choking or gagging
- Gasping
- Face reddened
- Older infants, children and adults
- Gradually progressive cough in spasms to severe Coughing Fits
- Starts as a dry, intermittent cough before progressing to a Paroxysmal cough
- Coughing spasms result from difficult clearing thick mucus in the trachea and Bronchi
- Patient feels as if cannot breath during coughing fit
- Typically breathing is unencumbered between Coughing Fits
- Post-tussive Emesis may occur
- May be asymptomatic between coughing episodes
- Inspiratory whoop
- Most common in young children
- Uncommon under age 6 months, and in teens and adults
- High pitched whooping sound triggered by gasping after a severe coughing spell
- Occurs when a deep breath is taken against a closed glottis
- Most common in young children
- Associated secondary conditions (from severe coughing spells)
- Subconjunctival Hemorrhage
- Back Pain
- Post-tussive Emesis
- Mallory Weiss Tear
- Cyanosis
- Cough Syncope
- Cough fracture (Rib Fracture)
- Petechiae (face and trunk)
- Pneuomothorax
- Pneumomediastinum
- Abdominal Hernia or Inguinal Hernia
- Urinary Incontinence
- Rectal Prolapse
- Gradually progressive cough in spasms to severe Coughing Fits
- Infants under age 6 months
- Convalescent Stage (2-3 weeks, may last months in young infants)
VI. Differential Diagnosis
- Catarrhal stage
- Viral Upper Respiratory Infection (e.g. Adenovirus)
- High fever suggests alternative diagnosis
- Paroxysmal stage
- See Cough Causes
- Mycoplasma pneumoniae
- Chlamydia pneumoniae
- RSV Bronchiolitis (esp. infants)
- Convalescent stage with persistent cough
- See Chronic Cough
- Asthma
- Gastroesophageal Reflux
- Acute Sinusitis with post nasal drainage
VII. Labs
- Specific bordatella testing
- See Bordetella Pertussis Test
- Bordatella PCR (preferred first-line)
- Sufficient accuracy alone (Pertussis Culture was previously recommended for confirmation)
- Much better Test Sensitivity than culture (best in first two weeks, wanes after 3-4 weeks)
- False negatives after 4 weeks of cough
- Lower Test Specificity than culture (higher False Positive Rate)
- Bordatella Pertussis Culture
- Low Test Sensitivity (best in first two weeks)
- False negatives occur at >2 weeks from cough onset
- High Specificity
- Pertussis Serology
- Consider in late presentation from onset of cough (4-12 weeks)
- Complete Blood Count
- Leukocytosis (esp. Lymphocytosis) from 15,000 to as high as 100,000
- Higher White Blood Cell Counts are associated with worse prognosis
VIII. Imaging
- Chest XRay
- Echocardiogram indications
- Pulmonary Hypertension suspected in severely ill children
IX. Diagnosis
- See Bordetella Pertussis Test
- Cough for less than one week is typically of viral origin
- Consider Pertussis when cough persists for longer than 2 weeks, especially when worsens over time or
- During local outbreaks or known Pertussis contact
- Clinical suspicion criteria (CDC clinical case definition)
- Major Criteria: Acute cough for 14 days
- Minor criteria (requires one)
- Paroxysmal cough
- Post-tussive Emesis
- Inspiratory Whoop
- Pertussis outbreak
- Precaution
- Requiring minor criteria misses a significant number of Pertussis cases
- Do not rely solely on CDC clinical case definition for Pertussis diagnosis (esp. minor criteria)
- Cornia (2010) JAMA 304(8): 890-6 [PubMed]
- Requiring minor criteria misses a significant number of Pertussis cases
X. Management: General
- Pertussis is a clinical diagnosis (see diagnosis above)
- Classic paroxysms of cough and the associated whoop, are often absent in adults
- Consider Pertussis in any patient with Chronic Cough, especially with suspected waning immunity
- Hospital Admission Indications
- All infants <4 months (and consider ICU admission)
- High risk of apnea and death
- Infants older than 4 months with severe symptoms, apnea, Cyanosis
- Children with serious comorbidity
- Cardiopulmonary disease
- Neurologic or muscular disorders
- Very high White Blood Cell Counts (associated with worse prognosis)
- All infants <4 months (and consider ICU admission)
- General Measures in severe cases (typically infants and young children)
- Exchange Transfusion
- Extracorporeal Membrane Oxygenation (ECMO)
- Treatment and reporting are based on clinical suspicion
- Test and treat empirically at time of testing if clinically suspect
- Do not delay antibiotics for test confirmation
- Test will return about the time a 5 day antibiotic course is completed
- Early treatment within 1-2 weeks has the best efficacy in preventing spread to contacts
- Antibiotics do not however otherwise alter course, complication rate or mortality
- Antibiotics eradicate B. Pertussis from nasopharynx
- Altunaiji (2007) Cochrane Database Syst Rev (3): CD004404 [PubMed]
- Do not delay antibiotics for test confirmation
- Antibiotic indications (for Pertussis treatment)
- Age <12 months: Within 6 weeks of onset of cough
- Age >12 months: Within 3 weeks of onset of cough
- Quarantine at time of diagnosis for 5 full days on antibiotics
- Or more if longer than three weeks since symptom onset
- Treat close contacts (asymptomic contacts need not be quarantined)
- Report clinically suspected cases before confirmation
- Test and treat empirically at time of testing if clinically suspect
- Antibiotic dosing
- Azithromycin (preferred first line option)
- Avoid shorter 3 day courses due to lack of supporting evidence
- Child: 10 mg/kg orally on day 1 and then 5 mg/kg daily for days 2-5
- Adult: 500 mg orally on day 1 and then 250 mg daily for days 2-5
- Other Macrolides
- Clarithromycin
- Child: 7.5 mg/kg twice daily for 7 days
- Adult: 500 mg orally twice daily for 7 days
- Erythromycin delayed release tablet
- Child: 40-60 mg/kg/day divided three to four times daily orally for 14 days
- Use with caution in young infants (risk of Hypertrophic Pyloric Stenosis)
- Adults: 666 mg orally three times daily orally for 14 days
- Child: 40-60 mg/kg/day divided three to four times daily orally for 14 days
- Clarithromycin
- Other agents with some efficacy against Pertussis (not as effective as Macrolides)
- Azithromycin (preferred first line option)
XI. Management: Prevention of spread
- Quarantine
- Pertussis patients are off work and out of school
- May return after 5 days on antibiotics or sooner if 3 weeks after paroxysmal stage ends
- Post-exposure Prophyaxis
- Indications
- Household exposures and other close contacts (including healthcare workers who did not wear masks)
- Especially infants under 6 months and pregnant women in third trimester AND
- Exposure to source patient within 21 days of cough onset
- Household exposures and other close contacts (including healthcare workers who did not wear masks)
- Protocol
- Contacts are typically asymptomatic and need not be quarantined
- Use same antibiotic course as above
- Monitor contacts for 3 weeks for onset of symptoms
- Post-exposure Vaccination indications
- Indications
XII. Prevention
- Precautions
- Adults are often the vector of Pertussis transmission to unimmunized or underimmunized children
- Adults tend to have subclinical persentations that are often missed
- Pertactin (a key Immunization component) is absent in some U.S. Pertussis strains as of 2013
- May result in decreased Immunization efficacy if pertactin-negative strains become more common
- Queenan (2013) N Engl J Med 368(6): 583-4 [PubMed]
- Adults are often the vector of Pertussis transmission to unimmunized or underimmunized children
- Diphtheria Tetanus Acellular Pertussis Vaccine (DTaP)
- Primary Series for 5 doses by age 5 years
- Tdap (Boostrix, Adacel)
- Age 7-10 years old for single catch-up dose if Primary Series with <5 DTaP doses or unknown status
- Age 11-18 years old: Single dose pimary series booster
- Age 18-64 years old: Single Tdap to replace any of the every 10 year Tetanus boosters
- Pregnant women in third trimester (repeat with each pregnancy)
XIII. Complications
- Infants
- Hospitalization
- Apnea (50% of infants)
- Superimposed Bacterial Pneumonia (20% of infants, with high mortality rate)
- Dehydration
- Encephalopathy
- Death (rate has been rising for infants)
- Teens and adults
- See Findings
- Prolonged cough (up to 6 weeks)
- Weight loss (33%)
- Urinary Incontinence (28%)
- Syncope (6%)
- Cough fracture (4%, Rib Fracture associated with severe coughing spells)
- Secondary Bacterial Pneumonia (2-4%)
- Otitis Media (most common infectious complication)
XIV. Resources
- CDC Pertussis
XV. References
- Aldeen and Rosenbaum (2017) 1200 Questions Emergency Medicine Boards, 3rd ed, Wolters Kluwer, Baltimore, p. 121
- Coffman (2005) Hospital Physician
- Gilbert (2001) Sanford Antimicrobial, p. 25
- Harrison and Ruttan (2019) Crit Dec Emerg Med 33(7): 3-12
- Takhar and Herbert in Majoewsky (2013) EM:Rap 13(4): 2-3
- Birkebaek (1999) Clin Infect Dis 29:1239-42 [PubMed]
- Gregory (2006) Am Fam Physician 74:420-7 [PubMed]
- Kline (2013) Am Fam Physician 88(8): 507-14 [PubMed]
- Tiwari (2005) MMWR Recomm Rep 54(RR-14): 1-16 [PubMed]